CSIMarket
 

Molecular Templates Inc   (NASDAQ: MTEM)

Molecular Templates Inc 's

Competitiveness




 

MTEM Sales vs. its Competitors Q2 2024



Comparing the current results to its competitors, Molecular Templates Inc reported Revenue increase in the 2 quarter 2024 by 0 % year on year.
The revenue growth was below Molecular Templates Inc 's competitors' average revenue growth of 169.49 %, achieved in the same quarter.

List of MTEM Competitors





Revenue Growth Comparisons




Net Income Comparison


Molecular Templates Inc recorded a net loss, as well as most of its competitors.

<<  MTEM Stock Performance Comparisons


Molecular Templates Inc 's Comment on Competition and Industry Peers


Molecular operates in the oncology and novel cancer therapies sector, competing with pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and other public and private research organizations. The company faces increasing competition driven by the development of new oncology drugs and therapies. Competitors often possess greater financial, manufacturing, marketing, drug development, technical, and human resources. Industry mergers and acquisitions may consolidate resources among fewer competitors. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborations with larger, established firms.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Molecular Templates Inc




Zynerba Pharmaceuticals Inc
Share Performance



+93.57%
One Year



Zynerba Pharmaceuticals Inc
Profile

Zynerba Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing innovative transdermal cannabinoid therapies. They utilize their proprietary technology to deliver cannabinoid molecules through the skin, providing targeted treatment for various medical conditions. Zynerba Pharmaceuticals aims to provide effective, safe, and convenient therapeutic options for patients in need.

More about Zynerba Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 65.195 mill. $ - mill. $ -37.582 mill.


Marinus Pharmaceuticals Inc
Share Performance



+64.33%
This Quarter



Marinus Pharmaceuticals Inc
Profile

Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.

More about Marinus Pharmaceuticals Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 31.476 mill. $ 31.466 mill. $ -140.491 mill.


Larimar Therapeutics Inc
Share Performance



-8.81%
30 Days



Larimar Therapeutics Inc
Profile

Larimar Therapeutics Inc's business model revolves around the development and commercialization of innovative therapeutics for the treatment of rare and serious genetic diseases.

More about Larimar Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -172.605 mill.


Lipocine Inc
Share Performance



-69.38%
This Year



Lipocine Inc
Profile

Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.

More about Lipocine Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 20.132 mill. $ 1.569 mill. $ -11.851 mill.


Kezar Life Sciences Inc
Share Performance



+15.90%
This Year



Kezar Life Sciences Inc
Profile

Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.

More about Kezar Life Sciences Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 53.537 mill. $ - mill. $ -45.233 mill.

39 more competitors available

Sign in to see all competitors

Sources: Molecular Templates Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Molecular Templates Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.